Histrelin
GnRH Agonist (implant / long-acting)Also known as: Vantas · Supprelin LA
A GnRH agonist delivered via subcutaneous implant releasing medication for 12 months. Approved for prostate cancer & central precocious puberty.
Typical Dose
50 mg implant releasing 65 mcg/day for 12 months
Route
Subcutaneous implant (inner upper arm)
Cycle
12-month implant; replaced annually
Half-life
Continuous 12-month release
Storage
Per manufacturer prior to implantation.
Overview
Histrelin is a GnRH agonist provided as a subcutaneous implant (Vantas for prostate cancer, Supprelin LA for precocious puberty) that releases drug continuously for 12 months. It is the longest-acting GnRH agonist delivery system available.
Quick Start Guide
Surgical implant — requires physician implantation. Not self-administered.
Research Indications
Advanced prostate cancer
Most EffectiveFDA approved. Produces sustained testosterone suppression to castrate levels with single annual implant.
Central precocious puberty
Most EffectiveFDA approved. Suppresses pubertal progression for 12 months per implant.
Research Protocols
Prostate cancer
OngoingDose
50 mg implant
Frequency
Annual replacement
Route
SubQ implant (inner arm)
Side Effects & Safety
Common
- Hot flashes
- Implant site reactions
- Sexual dysfunction
Uncommon
- Implant extrusion
- Bone loss
When to Stop
- Implant infection or extrusion
- Signs of hypersensitivity
How to Reconstitute
Clinical implantation procedure only.
Dosing math: Not applicable.
Quality Indicators
Good — use as normal
- Per manufacturer
Discard immediately
- Per manufacturer
What to Expect
Week 1–4
Initial flare then testosterone suppression to castrate levels by day 28.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample